0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Muscarinic Receptors in the Posterior Pituitary Gland

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The characteristics of atropine-sensitive binding of l-[<sup>3</sup>H]-quinuclidinyl benzilate ([<sup>3</sup>H]-QNB) to membrane re-suspensions of sheep posterior pituitary indicate that the binding sites represent muscarinic cholinergic receptors. Scat-chard plots of 6 saturation experiments showed a single class of binding sites, with an equilibrium dissociation constant of 16 ± 2 p M and a density equivalent to 1.8 ± 0.2 pmol/g wet weight of tissue. Kinetic analysis of 2 association and 3 dissociation curves yielded mean association and dissociation rate constants of 3.9 × 10<sup>8</sup> M<sup>–1</sup> min<sup>–1</sup> and 4.3 × 10<sup>–3</sup> min<sup>–1</sup>, respectively. The binding had a detailed pharmacology for 12 drugs consistent with muscarinic receptor identification. In rat neurointermediate lobes, superior cervical ganglionectomy had no demonstrable effect on [<sup>3</sup>H]-QNB binding. The location(s) and functional role(s) of neurohypophyseal muscarinic receptors remain to be elucidated.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1981
          1981
          26 March 2008
          : 32
          : 1
          : 33-37
          Affiliations
          Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Md., USA
          Article
          123126 Neuroendocrinology 1981;32:33–37
          10.1159/000123126
          7464988
          © 1981 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Categories
          Original Paper

          Comments

          Comment on this article